Αποτελέσματα Αναζήτησης
8 Φεβ 2023 · Cancer patients are at an increased risk for low testosterone due to chronic inflammation, cachexia, obesity, immunotherapy, chemotherapy, opioids, and/or androgen deprivation therapy [2••]. TD is associated with increased fatigue and anxiety and decreased feelings of well-being and overall survival [3, 4].
22 Φεβ 2010 · A new study has found that many male cancer survivors who develop testosterone deficiency after receiving chemotherapy or radiation therapy have an impaired quality of life and reduced energy...
12 Νοε 2019 · Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7–12 nmol/l).
This study then evaluated the effect of TRT on mortality in men in the low T group that was divided into men who did and did not receive TRT. Mortality was significantly higher in the untreated group, with a rate of 20.11% versus 9.38% in the TRT group ( p = 0.002).
25 Μαΐ 2023 · In men, androgen-deprivation therapy, multi-agent chemotherapy and medical comorbidities often exacerbate sexual dysfunction. Data from a meta-analysis of 43 studies addressing sexual function...
1 Ιουν 2010 · In 2005, a meta-analysis of the adverse effects of testosterone replacement therapy (6) showed that elevated hematocrit and an increase in a composite of prostate-related events were the most common side effects of testosterone replacement therapy.
20 Δεκ 2017 · In patients treated with ADT for ≤18 months, testosterone recovers to the OH level more often and faster after ADT cessation. Age, SHBG level, initial testosterone level, and ADT duration are associated with testosterone recovery. Keywords: Androgen deprivation therapy, Prostatic neoplasms, Testosterone.
